| Catalog No. | Size | Price (USD) |
| 16742-H08H-20 | 20 µg | $342.14 |
| 16742-H08H-50 | 50 µg | $476.92 |
| 16742-H08H-100 | 100 µg | $862.01 |
| 16742-H08H-500 | 500 µg | $1,966.91 |
General Information
| Formulation | Lyophilized from sterile PBS, pH 7.4. Please contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| Endotoxin | < 1.0 EU per μg protein as determined by the LAL method. |
| Shipping | In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature. Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise. |
| Stability & Storage | Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
| Reconstitution | To find reconstitution info, click on 'COA' at the top of the page, enter the lot number and product size for the lot-specific COA. |
| Purity | ≥ 95 % as determined by SDS-PAGE. ≥ 95 % as determined by SEC-HPLC. |
| Activity | Testing in progress |
| Protein Construction | A DNA sequence encoding the human LILRB4 (NP_001265357.2) (Met1-Glu259) was expressed with a polyhistidine tag at the C-terminus. |
| Accession# | NP_001265357.2 |
| Expressed Host | HEK293 Cells |
| Species | Human |
| Predicted N Terminal | Gln 22 |
| Molecule Mass | The recombinant human LILRB4 consists of 249 amino acids and predicts a molecular mass of 27.7 kDa. As a result of glycosylation, it migrates as an approximately 35-42 KDa band in SDS-PAGE under reducing conditions. |
Synonyms: B4 Protein, Human; CD85K Protein, Human; HM18 Protein, Human; ILT-3 Protein, Human; ILT3 Protein, Human; LIR-5 Protein, Human; LIR5 Protein, Human
Image / Experimental Information
| Image 1 Alt Text | Human LILRB4/CD85k/ILT3 Protein 15102 |
| Image 1 URL | Source image |
| Image 2 Alt Text | Human ILT3 Protein 36367 |
| Image 2 URL | Source image |
Background Information
| Full Name | leukocyte immunoglobulin like receptor B4 |
| Description | LILRB4 (Leukocyte Immunoglobulin Like Receptor B4) is a Protein Coding gene. This gene is a member of the leukocyte immunoglobulin-like receptor (LIR) family, which is found in a gene cluster at chromosomal region 19q13.4. The receptor is expressed on immune cells where it binds to MHC class I molecules on antigen-presenting cells and transduces a negative signal that inhibits stimulation of an immune response. The receptor can also function in antigen capture and presentation. LILRB4 is believed to down-regulate activation signals mediated by non-receptor tyrosine kinase cascades through the recruitment of SHP-1. LILRB4 is associated with the pathological processes of various inflammatory diseases. The LILRB4 is a central inhibitory receptor in Uterine dendritic cells (uDCs) that plays essential immune-regulatory roles at the maternal-fetal interface. |
title: Direct Small Molecule Modulation of LILRB4 (ILT3) Restores Antitumor Immunity In Vivo and in Patient-Derived Cells.
authors: Somaya A Abdel-Rahman; Zamara Mariam; ...; Moustafa T Gabr
journal: ACS chemical biology
date: 2026-07-26
pmid: 42503804
doi: 10.1021/acschembio.6c00486
cited_by_count: 0
techniques: Binding Assay; Concentration Assay; Fluorescence; Incubation; Labeling; Recombinant
bioz_score: 94
title: From DNA-encoded library (DEL) screening to in vivo validation: LILRB4 (ILT3)-targeted small molecules reprograms myeloid immune suppression.
authors: Somaya A Abdel-Rahman; Moustafa T Gabr
journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
date: 2026-07-06
pmid: 42407324
doi: 10.1016/j.biopha.2026.119740
cited_by_count: 0
techniques: Labeling; Microscale Thermophoresis
bioz_score: 94
title: Direct Small Molecule Modulation of LILRB4 (ILT3) Restores Anti-Tumor Immunity In Vivo and in Patient-Derived Cells
authors: Abdel-Rahman Somaya A.; Mariam Zamara; ...; Gabr Moustafa T.
journal: bioRxiv
date: 2026-06-11
doi: 10.64898/2026.06.10.731269
cited_by_count: 0
techniques: Binding Assay; Concentration Assay; Fluorescence; Incubation; Labeling; Recombinant
bioz_score: 94
title: Targeting the Myeloid Immune Checkpoint ILT3 (LILRB4) with Small Molecules Enables Reprogramming of Suppressive Tumor Immunity
authors: Abdel-Rahman Somaya A.; Monari Antonio; ...; Gabr Moustafa T.
journal: bioRxiv
date: 2026-06-09
doi: 10.64898/2026.06.05.730341
cited_by_count: 0
techniques: Activity Assay; Binding Assay; Biomarker Discovery; Blocking Assay; Competitive Binding Assay; Concentration Assay; Derivative Assay; Drug discovery; Enzyme-linked Immunosorbent Assay; Expressing; Fluorescence; Functional Assay; Incubation; Inhibition; Labeling; Positive Control; Produced; Protein Binding; Protein-Protein interactions; Recombinant; Solvent
bioz_score: 94
title: Anti-LILRB4 antibodies and derivative products
authors: An Song; Tao Huang; ...; X. Charlene Liao
date: 2026-02-24
cited_by_count: 0
techniques: Activity Assay; Binding Assay; FACS; Recombinant; SPR Assay; Software
bioz_score: 94
title: Discovery of galectin-8 as an LILRB4 ligand driving M-MDSCs defines a class of antibodies to fight solid tumors
authors: Yiting Wang; Yufan Sun; ...; Jie Xu
journal: Cell Reports Medicine
date: 2024-01-16
pmid: 38232701
doi: 10.1016/j.xcrm.2023.101374
pmcid: 10829871
cited_by_count: 24
techniques: Enzyme-linked Immunosorbent Assay; Incubation; Recombinant; Silver Staining
bioz_score: 94
title: Anti-ILT3 antibodies and antibody drug conjugates
authors: Jaime Darce; Scott Michael Lonning; ...; Aleksandr Tkachev
date: 2022-03-08
cited_by_count: 0
techniques: Activity Assay; Construct; Electroporation; In Vivo; Injection; Mouse Assay; Recombinant
bioz_score: 94
title: LILRB4-Targeting Antibody-Drug Conjugates for the Treatment of Acute Myeloid Leukemia
authors: Yasuaki Anami; Mi Deng; ...; Kyoji Tsuchikama
journal: Molecular Cancer Therapeutics
date: 2020-09-02
doi: 10.1158/1535-7163.mct-20-0407
cited_by_count: 27
techniques: Binding Assay; Enzyme-linked Immunosorbent Assay; High Performance Liquid Chromatography; Incubation; Recombinant
bioz_score: 94
title: Disrupting LILRB4/APOE Interaction by an Efficacious Humanized Antibody Reverses T-cell Suppression and Blocks AML Development
authors: Xun Gui; Mi Deng; ...; Zhiqiang An
journal: Cancer Immunology Research
date: 2019-06-18
doi: 10.1158/2326-6066.cir-19-0036
cited_by_count: 46
techniques: Enzyme-linked Immunosorbent Assay; Isolation
bioz_score: 94
